wellesenterprises
- Eli Lilly’s oral GLP-1 Foundayo (orforglipron) for weight loss had 5,612 fills in its third week of availability, per IQVIA data.
- Foundayo, which launched in April, is competing with Novo Nordisk’s (NVO) oral Wegovy (semaglutide), which hit the market in January. However, uptake
